Synergistic effects of GSK3 and p38 MAPK inhibitors on growth of plasmodium falciparum ex vivo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pharmacological inhibitors of glycogen synthase kinase 3 (GSK3) and p38 mitogen-activated protein kinase (p38 MAPK), two kinases commonly associated with signaling within cells, have been shown to suppress in vivo or ex vivo growth of plasmodial sp. Here we evaluated antiplasmodial activities ex vivo of four inhibitors against GSK3 [lithium chloride (LiCl), kenpaullone, (2'Z, 3'E)-6-bromoindirubin-3'-oxime (BIO) and SB216763]; and two against p38 MAPK (RWJ67657 and SB202190) individually and in combination preparatory to understanding the role of protein kinases in plasmodial development. The order of decreasing growth-suppressing potencies of the GSK3 inhibitors tested against Plasmodium falciparum 3D7 cultured ex vivo in erythrocytes was BIO (IC50=3.13 μM) > kenpaullone (IC50 = 18.3 μM) > SB216763 (IC50= 27.12 μM) > LiCl (IC50= 25 468 μM). The p38 MAPK inhibitor, RWJ67657, displayed an IC50 of 7.52 μM against 3D7. SB202190 was less effective at inhibiting 3D7 displaying an IC50 of 14.80 μM. When tested in combination, marked synergism was observed for combination of BIO or SB216763 with RWJ67657. In conclusion, GSK3 and MAPK inhibitors showed potent antiplasmodial activities. Synergistic effects observed between BIO or SB216763 and RWJ67657 in inhibiting plasmodial growth may implicate interaction between MAPK and GSK3 pathways and warrant further investigation.

Original languageEnglish
Pages (from-to)65-71
Number of pages7
JournalMalaysian Applied Biology
Volume43
Issue number1
Publication statusPublished - 2014

Fingerprint

Glycogen Synthase Kinase 3
Plasmodium falciparum
p38 Mitogen-Activated Protein Kinases
Protein Kinase Inhibitors
mitogen-activated protein kinase
Inhibitory Concentration 50
inhibitory concentration 50
oximes
kenpaullone
Oximes
Growth
Lithium Chloride
lithium chloride
antimalarials
Mitogen-Activated Protein Kinase Kinases
synergism
protein kinases
Protein Kinases
tau-protein kinase
phosphotransferases (kinases)

Keywords

  • GSK3
  • Inhibitors
  • Malaria
  • MAPK
  • Plasmodium falciparum

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

@article{7647b7ff9fa249c1b6db2cc7eb3cd560,
title = "Synergistic effects of GSK3 and p38 MAPK inhibitors on growth of plasmodium falciparum ex vivo",
abstract = "Pharmacological inhibitors of glycogen synthase kinase 3 (GSK3) and p38 mitogen-activated protein kinase (p38 MAPK), two kinases commonly associated with signaling within cells, have been shown to suppress in vivo or ex vivo growth of plasmodial sp. Here we evaluated antiplasmodial activities ex vivo of four inhibitors against GSK3 [lithium chloride (LiCl), kenpaullone, (2'Z, 3'E)-6-bromoindirubin-3'-oxime (BIO) and SB216763]; and two against p38 MAPK (RWJ67657 and SB202190) individually and in combination preparatory to understanding the role of protein kinases in plasmodial development. The order of decreasing growth-suppressing potencies of the GSK3 inhibitors tested against Plasmodium falciparum 3D7 cultured ex vivo in erythrocytes was BIO (IC50=3.13 μM) > kenpaullone (IC50 = 18.3 μM) > SB216763 (IC50= 27.12 μM) > LiCl (IC50= 25 468 μM). The p38 MAPK inhibitor, RWJ67657, displayed an IC50 of 7.52 μM against 3D7. SB202190 was less effective at inhibiting 3D7 displaying an IC50 of 14.80 μM. When tested in combination, marked synergism was observed for combination of BIO or SB216763 with RWJ67657. In conclusion, GSK3 and MAPK inhibitors showed potent antiplasmodial activities. Synergistic effects observed between BIO or SB216763 and RWJ67657 in inhibiting plasmodial growth may implicate interaction between MAPK and GSK3 pathways and warrant further investigation.",
keywords = "GSK3, Inhibitors, Malaria, MAPK, Plasmodium falciparum",
author = "L. Marhalim and Embi, {Mohammed Noor} and {Mohd. Sidek}, Hasidah",
year = "2014",
language = "English",
volume = "43",
pages = "65--71",
journal = "Malaysian Applied Biology",
issn = "0126-8643",
publisher = "Malaysian Society of Applied Biology",
number = "1",

}

TY - JOUR

T1 - Synergistic effects of GSK3 and p38 MAPK inhibitors on growth of plasmodium falciparum ex vivo

AU - Marhalim, L.

AU - Embi, Mohammed Noor

AU - Mohd. Sidek, Hasidah

PY - 2014

Y1 - 2014

N2 - Pharmacological inhibitors of glycogen synthase kinase 3 (GSK3) and p38 mitogen-activated protein kinase (p38 MAPK), two kinases commonly associated with signaling within cells, have been shown to suppress in vivo or ex vivo growth of plasmodial sp. Here we evaluated antiplasmodial activities ex vivo of four inhibitors against GSK3 [lithium chloride (LiCl), kenpaullone, (2'Z, 3'E)-6-bromoindirubin-3'-oxime (BIO) and SB216763]; and two against p38 MAPK (RWJ67657 and SB202190) individually and in combination preparatory to understanding the role of protein kinases in plasmodial development. The order of decreasing growth-suppressing potencies of the GSK3 inhibitors tested against Plasmodium falciparum 3D7 cultured ex vivo in erythrocytes was BIO (IC50=3.13 μM) > kenpaullone (IC50 = 18.3 μM) > SB216763 (IC50= 27.12 μM) > LiCl (IC50= 25 468 μM). The p38 MAPK inhibitor, RWJ67657, displayed an IC50 of 7.52 μM against 3D7. SB202190 was less effective at inhibiting 3D7 displaying an IC50 of 14.80 μM. When tested in combination, marked synergism was observed for combination of BIO or SB216763 with RWJ67657. In conclusion, GSK3 and MAPK inhibitors showed potent antiplasmodial activities. Synergistic effects observed between BIO or SB216763 and RWJ67657 in inhibiting plasmodial growth may implicate interaction between MAPK and GSK3 pathways and warrant further investigation.

AB - Pharmacological inhibitors of glycogen synthase kinase 3 (GSK3) and p38 mitogen-activated protein kinase (p38 MAPK), two kinases commonly associated with signaling within cells, have been shown to suppress in vivo or ex vivo growth of plasmodial sp. Here we evaluated antiplasmodial activities ex vivo of four inhibitors against GSK3 [lithium chloride (LiCl), kenpaullone, (2'Z, 3'E)-6-bromoindirubin-3'-oxime (BIO) and SB216763]; and two against p38 MAPK (RWJ67657 and SB202190) individually and in combination preparatory to understanding the role of protein kinases in plasmodial development. The order of decreasing growth-suppressing potencies of the GSK3 inhibitors tested against Plasmodium falciparum 3D7 cultured ex vivo in erythrocytes was BIO (IC50=3.13 μM) > kenpaullone (IC50 = 18.3 μM) > SB216763 (IC50= 27.12 μM) > LiCl (IC50= 25 468 μM). The p38 MAPK inhibitor, RWJ67657, displayed an IC50 of 7.52 μM against 3D7. SB202190 was less effective at inhibiting 3D7 displaying an IC50 of 14.80 μM. When tested in combination, marked synergism was observed for combination of BIO or SB216763 with RWJ67657. In conclusion, GSK3 and MAPK inhibitors showed potent antiplasmodial activities. Synergistic effects observed between BIO or SB216763 and RWJ67657 in inhibiting plasmodial growth may implicate interaction between MAPK and GSK3 pathways and warrant further investigation.

KW - GSK3

KW - Inhibitors

KW - Malaria

KW - MAPK

KW - Plasmodium falciparum

UR - http://www.scopus.com/inward/record.url?scp=84904186379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904186379&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 65

EP - 71

JO - Malaysian Applied Biology

JF - Malaysian Applied Biology

SN - 0126-8643

IS - 1

ER -